Interestingly, emactuzumab, an anti-human CD115 mAb, reduced the number of CD163 + CD206 + M2 macrophages in melanoma patients by depleting immature TAMs before the IL-4-stimulated phase [198]. This evidence concerns the gene CD163 and melanoma.